• Je něco špatně v tomto záznamu ?

Molecular Cytogenetic Analysis of Chromosome 8 Aberrations in Patients With Multiple Myeloma Examined in 2 Different Stages, at Diagnosis and at Progression/Relapse

M. Mlynarcikova, J. Balcarkova, P. Mickova, V. Scudla, T. Pika, J. Bacovsky, J. Minarik, E. Janousova, M. Jarosova,

. 2016 ; 16 (6) : 358-365. [pub] 20160227

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc17024085

Grantová podpora
NT14400 MZ0 CEP - Centrální evidence projektů

BACKGROUND: The genome of multiple myeloma (MM) clonal plasma cells is characterized by genetic changes of prognostic importance. Disease progression is accompanied by a number of secondary chromosomal aberrations including chromosome 8. We focused on the detection of chromosome 8 aberrations in patients with MM who were examined at 2 different phases: diagnosis and progression/relapse. PATIENTS AND METHODS: A total of 62 patients with MM were examined at the time of diagnosis and at relapse/progression. The median age was 64 years (range, 39-78 years); the study included 29 males and 33 females. We analyzed bone marrow samples for detecting aberrations on chromosome 8 by the fluorescence immunophenotyping and interphase cytogenetics as a tool for the investigation of neoplasms (FICTION) and fluorescence in situ hybridization methods with specific probes. RESULTS: Chromosome 8 aberrations were detected in 24 (38.7%) patients at diagnosis and in 29 (46.8%) patients at progression/relapse. Only 5 (8%) patients developed additional chromosome 8 changes at progression/relapse. The aberrations were heterogeneous, involving numerical and structural changes of the MYC gene. Aberrations of the short arm of chromosome 8, involving the genes TRAIL-R1/-R2, were less frequent (4 of 62 patients, 6.4%). All aberrations of chromosome 8 were accompanied with additional changes and with an advanced clinical phase of the disease. This finding significantly influenced the overall survival of patients. CONCLUSION: In the current study, chromosome 8 aberrations were highly heterogeneous, were presented at diagnosis in patients with advanced clinical stage, and were associated with worse overall survival. We have not confirmed the increase of frequency aberration of chromosome 8 in disease progression. The findings demonstrate the importance of fluorescence in situ hybridization examination of chromosome 8 in newly diagnosed patients with MM.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17024085
003      
CZ-PrNML
005      
20191107133112.0
007      
ta
008      
170720s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.clml.2016.02.038 $2 doi
035    __
$a (PubMed)27052024
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Mlynarcikova, Miroslava $u Department of Hemato-oncology, Palacky University Hospital, Olomouc, Czech Republic.
245    10
$a Molecular Cytogenetic Analysis of Chromosome 8 Aberrations in Patients With Multiple Myeloma Examined in 2 Different Stages, at Diagnosis and at Progression/Relapse / $c M. Mlynarcikova, J. Balcarkova, P. Mickova, V. Scudla, T. Pika, J. Bacovsky, J. Minarik, E. Janousova, M. Jarosova,
520    9_
$a BACKGROUND: The genome of multiple myeloma (MM) clonal plasma cells is characterized by genetic changes of prognostic importance. Disease progression is accompanied by a number of secondary chromosomal aberrations including chromosome 8. We focused on the detection of chromosome 8 aberrations in patients with MM who were examined at 2 different phases: diagnosis and progression/relapse. PATIENTS AND METHODS: A total of 62 patients with MM were examined at the time of diagnosis and at relapse/progression. The median age was 64 years (range, 39-78 years); the study included 29 males and 33 females. We analyzed bone marrow samples for detecting aberrations on chromosome 8 by the fluorescence immunophenotyping and interphase cytogenetics as a tool for the investigation of neoplasms (FICTION) and fluorescence in situ hybridization methods with specific probes. RESULTS: Chromosome 8 aberrations were detected in 24 (38.7%) patients at diagnosis and in 29 (46.8%) patients at progression/relapse. Only 5 (8%) patients developed additional chromosome 8 changes at progression/relapse. The aberrations were heterogeneous, involving numerical and structural changes of the MYC gene. Aberrations of the short arm of chromosome 8, involving the genes TRAIL-R1/-R2, were less frequent (4 of 62 patients, 6.4%). All aberrations of chromosome 8 were accompanied with additional changes and with an advanced clinical phase of the disease. This finding significantly influenced the overall survival of patients. CONCLUSION: In the current study, chromosome 8 aberrations were highly heterogeneous, were presented at diagnosis in patients with advanced clinical stage, and were associated with worse overall survival. We have not confirmed the increase of frequency aberration of chromosome 8 in disease progression. The findings demonstrate the importance of fluorescence in situ hybridization examination of chromosome 8 in newly diagnosed patients with MM.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a nádorové biomarkery $7 D014408
650    12
$a chromozomální aberace $7 D002869
650    12
$a lidské chromozomy, pár 8 $7 D002898
650    _2
$a klonální evoluce $7 D060965
650    _2
$a cytogenetické vyšetření $7 D020732
650    _2
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a geny myc $7 D016259
650    _2
$a lidé $7 D006801
650    _2
$a imunofenotypizace $7 D016130
650    _2
$a hybridizace in situ fluorescenční $7 D017404
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mnohočetný myelom $x diagnóza $x genetika $x mortalita $x terapie $7 D009101
650    _2
$a staging nádorů $7 D009367
650    _2
$a recidiva $7 D012008
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Balcárková, Jana $u Department of Hemato-oncology, Palacky University Hospital, Olomouc, Czech Republic. $7 xx0085195
700    1_
$a Mickova, Pavla $u Department of Hemato-oncology, Palacky University Hospital, Olomouc, Czech Republic.
700    1_
$a Ščudla, Vlastimil, $u Department of Hemato-oncology, Palacky University Hospital, Olomouc, Czech Republic. $d 1946- $7 jn20000402953
700    1_
$a Pika, Tomáš $u Department of Hemato-oncology, Palacky University Hospital, Olomouc, Czech Republic. $7 xx0071238
700    1_
$a Bačovský, Jaroslav $u Department of Hemato-oncology, Palacky University Hospital, Olomouc, Czech Republic. $7 xx0053311
700    1_
$a Minařík, Jiří $u Department of Hemato-oncology, Palacky University Hospital, Olomouc, Czech Republic. $7 xx0106330
700    1_
$a Koriťáková, Eva, $u Institute of Biostatistics and Analysis, Masaryk University, Brno, Czech Republic. $d 1986- $7 xx0159601
700    1_
$a Jarošová, Marie, $u Department of Hemato-oncology, Palacky University Hospital, Olomouc, Czech Republic. Electronic address: Marie.Jarosova@fnol.cz. $d 1950- $7 xx0053403
773    0_
$w MED00180199 $t Clinical lymphoma, myeloma & leukemia $x 2152-2669 $g Roč. 16, č. 6 (2016), s. 358-365
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27052024 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20191107133344 $b ABA008
999    __
$a ok $b bmc $g 1239766 $s 984998
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 16 $c 6 $d 358-365 $e 20160227 $i 2152-2669 $m Clinical lymphoma, myeloma & leukemia $n Clin Lymphoma Myeloma Leuk $x MED00180199
GRA    __
$a NT14400 $p MZ0
LZP    __
$a Pubmed-20170720

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...